home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 12/16/25

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 16, 2025 /CNW/ -- USANewsGroup.com   News Commentary – Gastrointestinal cancers that once re...
AIM - AI-Media Launches ADA Title II Compliance Initiative to Support Public Entities Meeting WCAG 2.1 AA Deadlines

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- AI-Media, a global leader in AI-powered captioning and audio description technology, today announced the launch of its comprehensive ADA Title II Compliance Initiative, aimed at helping state and local governments across the United States meet the newly...

AIM - AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series

OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Closing Bell Series ...

AIM - AIM ImmunoTech GAAP EPS of -$1.57 misses by $0.59

2025-11-18 15:42:04 ET More on AIM ImmunoTech Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech Read the full article on Seeking Alpha For further details see: ...
AIM - AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third quarter 2025. “The third quarter was marked by sol...

AIM - AI-Media and AVE Announce Exclusive Partnership to Power Accessibility Across Australia's Live Events

SYDNEY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- AI-Media , a global leader in AI-powered live captioning and accessibility solutions, has appointed Audio Visual Events (AVE) as its exclusive rental partner for the live events market in Australia . This strategic partnership combines...

AIM - AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen ...
AIM - AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen &...

AIM - AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled “Compositions f...

AIM - AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit , taking place October 22-23, 2025 in New York, NY. This prestigious ev...
Previous 10 Next 10